News

◄ Back

November 18, 2005 Germantown, WI USA: Cambridge Major Laboratories today announced that successful FDA inspections were conducted during the weeks of October 31st and November 7th 2005, respectively. Both of the Company’s Active Pharmaceutical Ingredient (API) manufacturing facilities were the subject of the inspections which included both pre-approval and general inspections. A total of two minor observations were noted across the Company’s two sites.

The inspections represent the first for Cambridge Major’s new state-of-the-art facility which came on-line in late 2004. Over the past year the Company has been transferring and validating numerous API’s in its new facility. Currently, Cambridge Major manufactures several commercial products including innovative new drugs, generic substances, and medical imaging agents.

“We have reached a significant milestone in our growth having constructed the new facility, and now can boast that it is truly an FDA-inspected site,” said Dr. Michael Major, President and CEO of Cambridge Major Labs. “The results of these inspections underscore Cambridge Major’s strong commitment to quality and regulatory excellence, and our team has put forth a tremendous effort to ensure the inspection of the new site was a success”.

◄ Back